Replies to post #1687 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

>Wouldn't many MDs go a little further and avoid prescribing to those in high risk groups for HIV (assuming a reasonable comparable alternative)? I would assume that many HBV patients are in this category.<

This is why companies need a salesforce! Many docs may not know that Tyzeka has an advantage vs other HBV agents in treating patients who are known to have HIV or are at high risk for getting it.

Ditto for pre-menopausal women with HBV, who comprise an even bigger patient pool that is well-matched for Tyzeka (#msg-21678801).

[go seek]

perhaps, but Baraclude is a very good HBV drug...
many factors to weigh...

i am not the best one to answer you question.

[flatlander_60048]

There is probably considerable overlap in the at risk populations since HBV is also transmitted by intervaneous drug use and unprotected sex.

FL